Clindamycin Injection (iv/im) Generics - Manufacturers & Suppliers
Cleocin, Clindamycin, Dalacin C(US); Dalacin C, Clindamycine(EU)
| Product/Composition:- | Clindamycin Injection (IV/IM) |
|---|---|
| Strength:- | 300 mg/2 mL, 600 mg/4 mL |
| Form:- | Injection (IV/IM) |
| Reference Brands:- | Cleocin, Clindamycin, Dalacin C(US); Dalacin C, Clindamycine(EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Clindamycin IV and IM inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, leading to bacterial cell death. It effectively treats severe skin, respiratory, and intra-abdominal infections. Benefits include rapid, reliable action against anaerobic bacteria, good tissue penetration, and clinical utility in hospital settings.
Clindamycin IV/IM is approved in the EU and US for severe bacterial infections, including skin, respiratory, and intra-abdominal infections. In the EU, brands like Cleocin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data; generic formulations are widely available. Both regions require detailed dossiers, including clinical trial results, manufacturing standards, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access for clindamycin IV/IM, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.